Generic Baxdela Availability
Last updated on Oct 9, 2024.
Baxdela is a brand name of delafloxacin, approved by the FDA in the following formulation(s):
BAXDELA (delafloxacin meglumine - powder;intravenous)
-
Manufacturer: MELINTA
Approval date: June 19, 2017
Strength(s): EQ 300MG BASE/VIAL [RLD]
BAXDELA (delafloxacin meglumine - tablet;oral)
-
Manufacturer: MELINTA
Approval date: June 19, 2017
Strength(s): EQ 450MG BASE [RLD]
Has a generic version of Baxdela been approved?
No. There is currently no therapeutically equivalent version of Baxdela available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Baxdela. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 12,036,219
Patent expiration dates:
- June 2, 2034✓
- June 2, 2034
-
Patent 7,635,773
Patent expiration dates:
- March 13, 2029✓
- March 13, 2029
-
Patent 7,728,143
Patent expiration dates:
- June 19, 2031✓
- June 19, 2031
-
Salt and crystalline forms thereof of a drug
Patent 8,252,813
Issued: August 28, 2012
Inventor(s): Zhang Geoff G. Z. & Bradley Michael F. & Barnes David M. & Henry Rodger
Assignee(s): Abbott LaboratoriesA crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Patent expiration dates:
- October 2, 2026✓✓
- October 2, 2026
-
Salt and crystalline forms thereof of a drug
Patent 8,273,892
Issued: September 25, 2012
Inventor(s): Zhang Geoff G. Z. & Bradley Michael F. & Barnes David M. & Henry Rodger
Assignee(s): Abbott LaboratoriesA crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Patent expiration dates:
- August 6, 2026✓
- August 6, 2026
-
Sulfoalkyl ether cyclodextrin compositions
Patent 8,410,077
Issued: April 2, 2013
Inventor(s): Antle Vincent
Assignee(s): CyDex Pharmaceuticals, Inc.SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Patent expiration dates:
- March 13, 2029✓
- March 13, 2029
-
Salt and crystalline forms thereof of a drug
Patent 8,648,093
Issued: February 11, 2014
Inventor(s): Zhang Geoff G. Z. & Bradley Michael F. & Barnes David M. & Henry Rodger
Assignee(s): Abbvie Inc.A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Patent expiration dates:
- October 7, 2025✓✓
- October 7, 2025
-
Process for making quinolone compounds
Patent 8,871,938
Issued: October 28, 2014
Inventor(s): Hanselmann Roger & Reeve Maxwell M. & Johnson Graham
Assignee(s): Melinta Therapeutics, Inc.The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.
Patent expiration dates:
- September 23, 2029✓
- September 23, 2029
-
Salt and crystalline forms thereof of a drug
Patent 8,969,569
Issued: March 3, 2015
Inventor(s): Zhang Geoff G. Z. & Bradley Michael F. & Barnes David M. & Henry Rodger
Assignee(s): AbbVie Inc.A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Patent expiration dates:
- October 7, 2025✓✓
- October 7, 2025
-
Sulfoalkyl ether cyclodextrin compositions
Patent 9,200,088
Issued: December 1, 2015
Inventor(s): Antle Vincent D.
Assignee(s): Cydex Pharmaceuticals, Inc.SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Patent expiration dates:
- March 13, 2029✓
- March 13, 2029
-
Alkylated cyclodextrin compositions and processes for preparing and using the same
Patent 9,493,582
Issued: November 15, 2016
Inventor(s): Antle Vincent D. & Lopes Alvaro & Monteiro Daniel
Assignee(s): Cydex Pharmaceuticals, Inc.The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
Patent expiration dates:
- February 27, 2033✓
- February 27, 2033
-
Salt and crystalline forms thereof of a drug
Patent 9,539,250
Issued: January 10, 2017
Inventor(s): Zhang Geoff G. Z. & Bradley Michael F. & Barnes David M. & Henry Rodger
Assignee(s): ABBVIE INC.A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Patent expiration dates:
- October 7, 2025✓✓✓
- October 7, 2025
-
Sulfoalkyl ether cyclodextrin compositions
Patent 9,750,822
Issued: September 5, 2017
Inventor(s): Antle Vincent D.
Assignee(s): Cydex Pharmaceuticals, Inc.SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Patent expiration dates:
- March 13, 2029✓
- March 13, 2029
-
Process for making quinolone compounds
Patent RE46617
Issued: November 28, 2017
Inventor(s): Hanselmann Roger & Reeve Maxwell M. & Johnson Graham
Assignee(s): MELINTA THERAPEUTICS, INC.The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.
Patent expiration dates:
- December 28, 2029✓
- December 28, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 19, 2022 - NEW CHEMICAL ENTITY
- June 19, 2027 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Baxdela (delafloxacin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: quinolones and fluoroquinolones
- Breastfeeding
- En español
Patient resources
- Baxdela drug information
- Baxdela (Delafloxacin Intravenous) (Advanced Reading)
- Baxdela (Delafloxacin Oral) (Advanced Reading)
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
